Saama's agreement with Pfizer to fundamentally change drug development processes, helping more people worldwide
Saama, a provider of AI-based solutions that accelerate clinical development and commercialization say the agreement represents the expansion of a strategic relationship that started in 2020. This was the year the company entered into a partnership with Pfizer to automate Pfizer’s data review processes with AI.
The result of that initial collaboration was Smart Data Quality (SDQ), which significantly cut down the time to database lock. With this new agreement, Pfizer will continue to scale SDQ to help streamline and accelerate its data review processes across its broader portfolio of global studies.
“Our initial collaboration with Pfizer for its COVID-19 vaccine demonstrated the unprecedented power of our AI-enabled technology platform to improve and accelerate the clinical trial process, and ultimately, its ability to help bring treatments to patients faster,” said Lisa Moneymaker, chief technology officer and chief product officer, at Saama.
“The opportunity to now scale across more of the Pfizer portfolio underscores the evidence-based potential of Saama’s one-of-a-kind platform to fundamentally change the way drug development is done to benefit more people around the world.”
Not limited to SDQ, the new agreement expands the existing relationship to help Pfizer accelerate regulatory submissions across its portfolio using Saama’s new advanced Biometrics Research and Analysis Information Network.
Saama says that Pfizer will now have the potential to reduce regulatory submission timelines across its portfolio, as this next-generation solution streamlines statistical programming and biostatistics workflows, digitizes study specifications, and generates submission-ready tables, listings, and figures (TLF) artifacts.
It will also set the stage for continuing automation and innovation to further accelerate future trial submissions.
“Building a sustainable framework to accelerate analysis and reporting for clinical trials is fundamental to speeding up the development of breakthrough medicines,” said Demetris Zambas, vice president and global head data monitoring and management, at Pfizer.
“We look forward to expanding our strategic partnership with Saama across our global portfolio, leveraging their cutting-edge, AI-based technologies to reduce the time and effort required for data review and reconciliation, and to improve the quality and consistency of data across routine and complex clinical studies alike.”
Saama’s says its solutions use the industry’s ‘most advanced technology and AI capabilities to give study teams the power to manage the high volume and variety of today’s clinical trial data’.
Throughout studies, data are centralized and standardized from multiple sources to enable streamlined medical review processes, improve patient safety oversight, predict participant behavior, accelerate clinical signal discovery, and more.
It says its platform of AI-enabled SaaS products and solutions supports the full spectrum of clinical development.
For those attending the SCOPE Summit in Orlando this week, the company invites you to meet them at booth 813 from February 11-14.
